Investment Rating - The report assigns an "Accumulate" rating for the company for the first time [2]. Core Views - The company is transitioning from a single large product-driven growth model to a multi-innovative drug-driven growth model, with several innovative drugs entering late-stage clinical trials and market launch [8][17]. - The company maintains a solid leading position in growth hormone products, with multiple innovative drugs opening up new growth opportunities [8][17]. - The newly launched products, such as the nano-crystal form of medroxyprogesterone and the IL-1β inhibitor, are expected to address significant market needs and have the potential to become major products [8][54]. Summary by Sections Company Overview - The company is a comprehensive development enterprise focused on gene-engineered biopharmaceuticals, with its main asset being Changchun Jinsai Pharmaceutical [13]. - The company has a broad business scope, including gene engineering drugs, biological vaccines, and modern traditional Chinese medicine [13]. Financial Performance - The company's revenue slightly declined, with a projected revenue of 13.466 billion yuan in 2024, a year-on-year decrease of 7.55% [8][16]. - The company’s net profit attributable to shareholders is expected to drop significantly in 2024, with a forecast of 2.583 billion yuan, a decrease of 43.01% year-on-year [7][16]. Product Pipeline and Innovation - The company is increasing its R&D investment, with R&D expenses rising from 349 million yuan in 2017 to 2.69 billion yuan in 2024, representing 19.97% of revenue [21][24]. - The company has multiple innovative products in the pipeline, including the recently approved IL-1β inhibitor, which marks a shift from a focus on growth hormones to a broader innovative drug strategy [23][54]. Market Opportunities - The newly launched nano-crystal form of medroxyprogesterone significantly improves patient compliance and accessibility, addressing the challenges of traditional formulations [31][53]. - The approval of the IL-1β inhibitor for acute gout attacks is expected to provide a new treatment option, enhancing the company's product offerings in the pain management market [54]. Revenue Forecast - The company is projected to achieve revenues of 134.08 billion yuan in 2025, 142.99 billion yuan in 2026, and 155.19 billion yuan in 2027, with corresponding net profits of 22.24 billion yuan, 23.01 billion yuan, and 24.58 billion yuan [8][7].

Core Viewpoint - Changchun Gaoxin announced that its subsidiary has received acceptance for the clinical trial application of GS3-007a dry mixed suspension, a drug aimed at treating pediatric growth hormone deficiency (PGHD) [1] Group 1: Product Development - GS3-007a is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical, classified as a Class 1 chemical drug [1] - The drug is intended for the treatment of PGHD, a common endocrine disorder in pediatrics that leads to short stature and delayed development in children [1] - The incidence of PGHD in China is approximately 1 in 8,600, with the majority of cases (about 70%) attributed to isolated growth hormone deficiency (GHD) due to insufficient secretion of growth hormone-releasing hormone (GHRH) [1] Group 2: Strategic Alignment - The development of GS3-007a aligns with the company's strategic focus on products for children's growth and development [1] - Currently, there are no similar products available in the domestic market, and the acceptance of this clinical trial application will facilitate the clinical development of the product and address unmet clinical needs for patients [1]

Investment Rating - The investment rating for the company is "Accumulate" [6][19]. Core Views - The report emphasizes that the core subsidiary, Jinsai Pharmaceutical, is increasing its investment in research and sales, which is impacting short-term profitability. The focus is on the innovation pipeline data and business development transactions as catalysts for growth, maintaining the "Accumulate" rating [2][12]. Financial Summary - Total revenue for 2023 is projected at 14,566 million, with a year-on-year growth of 15.4%. However, a decline of 7.6% is expected in 2024, followed by a slight decrease of 0.3% in 2025, and a recovery with growth of 2.8% in 2026 and 2.7% in 2027 [4]. - Net profit attributable to the parent company is forecasted to be 4,532 million in 2023, with a significant drop of 43.0% to 2,583 million in 2024. The net profit is expected to further decline to 2,148 million in 2025, before recovering to 2,376 million in 2026 and 2,525 million in 2027 [4]. - Earnings per share (EPS) is projected to decrease from 11.11 yuan in 2023 to 5.26 yuan in 2025, with a gradual increase to 6.19 yuan by 2027 [4]. Market Data - The company's target price is set at 157.94 yuan, with the current price at 127.49 yuan [6][12]. - The market capitalization is reported at 52,008 million, with a 52-week price range of 78.90 to 128.00 yuan [7]. Investment Highlights - Jinsai Pharmaceutical, as a leader in the growth hormone industry, is expected to maintain its competitive edge despite a deteriorating competitive landscape for long-acting growth hormones. The company has five years of real-world data proving the safety of its long-acting products and has received approvals for three major indications [12]. - The report highlights the diversification of product revenue, with a focus on new key products such as Jinbeixin and Meishiya, which are expected to capture significant market potential [12]. - The company has a rich pipeline of research projects, with several candidates expected to submit IND applications in the second half of the year, indicating potential for international market expansion [12].

Core Points - Changchun High-tech announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry suspension for domestic production [1] Group 1 - The acceptance of the clinical trial application indicates progress in the development of GS3-007a, which may enhance the company's product pipeline [1] - This regulatory approval is a significant step for Changchun Jinsai Pharmaceutical in advancing its research and development efforts [1]

Core Viewpoint - Changchun Gaoxin announced that its subsidiary, Changchun Jinsai Pharmaceutical, received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a [1] Group 1: Company Developments - Changchun Jinsai Pharmaceutical's GS3-007a is an orally administered small molecule growth hormone secretagogue developed independently by the company [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of pediatric growth hormone deficiency (PGHD) caused by endogenous growth hormone deficiency [1]

Core Viewpoint - Changchun High-tech has received approval for the clinical trial application of its self-developed oral growth hormone secretagogue, GS3-007a, aimed at treating pediatric growth hormone deficiency (PGHD) [1][2] Group 1: Product Development - GS3-007a is classified as a Class 1 chemical drug and is designed for children with PGHD, a common endocrine disorder leading to stunted growth [1] - The incidence of PGHD in China is approximately 1 in 8600, with around 510 million children affected by short stature, and about 230,000 diagnosed cases [1] - The product offers an alternative to existing treatments, which require subcutaneous injections, by providing a daily oral administration option [2] Group 2: Strategic Alignment - The development of GS3-007a aligns with the company's strategic focus on pediatric growth and development products, addressing unmet clinical needs in this area [2] - There are currently no similar products available in the domestic market, indicating a potential competitive advantage for the company [2] Group 3: Recent Developments - Changchun High-tech has recently announced multiple approvals for clinical trial applications from its subsidiary, Jinsai Pharmaceutical, including other innovative drug candidates [3] - The company has also received FDA approval for a hypertension treatment, showcasing its expanding product portfolio [3][4]

Group 1 - The core point of the article is that Changchun High-tech (000661) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a suspension [1] - GS3-007a is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical, classified as a Class 1 chemical drug [1] - The drug is intended for the treatment of pediatric growth hormone deficiency (PGHD) caused by endogenous growth hormone deficiency [1]

Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., received the Acceptance Notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry mixed suspension, marking a significant step in the development of this drug [1] Group 1 - The GS3-007a dry mixed suspension is an orally administered small molecule growth hormone secretagogue developed by Jinsai Pharmaceutical [1] - The drug is classified as a Class 1 chemical drug and is intended for the treatment of pediatric growth hormone deficiency (PGHD) caused by endogenous growth hormone deficiency [1]

格隆汇9月8日丨长春高新(000661.SZ)公布，控股子公司——长春金赛药业有限责任公司（简称"金赛药 业"）收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GS3-007a干混悬剂境内生产药品 注册临床试验申请获得受理。GS3-007a干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药 物，注册分类为化药1类，拟用于因内源性生长激素缺乏所引起的儿童生长缓慢（PGHD）的治疗。 ...

Group 1 - The core point of the article is that Changchun High New Technology Industry Group Co., Ltd. announced that its subsidiary, Jinsai Pharmaceutical, has received the acceptance notice from the National Medical Products Administration for the clinical trial application of GS3-007a dry suspension, which is intended for treating growth retardation in children due to endogenous growth hormone deficiency [1] Group 2 - The drug GS3-007a is specifically aimed at addressing the issue of growth retardation in children, indicating a targeted therapeutic approach in the pediatric market [1] - The acceptance of the clinical trial application marks a significant step in the drug development process, potentially leading to future commercialization if trials are successful [1] - This development reflects the ongoing efforts within the pharmaceutical industry to innovate and provide solutions for unmet medical needs, particularly in pediatric healthcare [1]